102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB1779

 

Introduced 2/17/2021, by Rep. Mary E. Flowers

 

SYNOPSIS AS INTRODUCED:
 
215 ILCS 5/356z.43 new

    Amends the Illinois Insurance Code to provide that an individual or group health care service plan contract that is issued, amended, delivered, or renewed on or after January 1, 2022 shall not require prior authorization for biomarker testing for an insured with advanced or metastatic stage 3 or 4 cancer, nor shall prior authorization be required for biomarker testing of cancer progression or recurrence in the insured with advanced or metastatic stage 3 or 4 cancer. Defines "biomarker testing".


LRB102 10161 BMS 18161 b

 

 

A BILL FOR

 

HB1779LRB102 10161 BMS 18161 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Insurance Code is amended by
5adding Section 356z.43 as follows:
 
6    (215 ILCS 5/356z.43 new)
7    Sec. 356z.43. Biomarker testing; advanced or metastatic
8stage 3 or 4 cancer.
9    (a) As used in this Section, "biomarker testing" means
10diagnostic testing of the cancer patient's biospecimen, such
11as tissue, blood, or other bodily fluids, for DNA or RNA
12alterations to identify an individual with a subtype of cancer
13in order to guide patient treatment.
14    (b) An individual or group health care service plan
15contract that is issued, amended, delivered, or renewed on or
16after January 1, 2022 shall not require prior authorization
17for biomarker testing for an insured with advanced or
18metastatic stage 3 or 4 cancer, nor shall prior authorization
19be required for biomarker testing of cancer progression or
20recurrence in the insured with advanced or metastatic stage 3
21or 4 cancer.